Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18539788 | 1.00 | CYSLTR2 (0.43) | CYSLTR2CYSLTR1TAAR1GPBAR1MME | |
| SCHEMBL11993594 | 0.90 | TAAR1 (0.45) | CYSLTR2CYSLTR1TAAR1GPBAR1MME | |
| SCHEMBL17031423 | 0.90 | TAAR1 (0.45) | CYSLTR2CYSLTR1TAAR1GPBAR1MME | |
| SCHEMBL18293493 | 0.89 | TAAR1 (0.43) | CYSLTR2CYSLTR1TAAR1 | |
| SCHEMBL13881670 | 0.89 | TAAR1 (0.43) | CYSLTR2CYSLTR1TAAR1 | |
| SCHEMBL18550938 | 0.89 | TAAR1 (0.43) | CYSLTR2CYSLTR1TAAR1 | |
| SCHEMBL4568796 | 0.84 | HIF1A (0.44) | CYSLTR2CYSLTR1 | |
| SCHEMBL4568963 | 0.84 | HIF1A (0.44) | CYSLTR2CYSLTR1 | |
| SCHEMBL4568809 | 0.84 | HIF1A (0.44) | CYSLTR2CYSLTR1 | |
| SCHEMBL4568906 | 0.83 | MAPK1 (0.50) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | CYSLTR2 456/4885CYSLTR1 417/4885TAAR1 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.